BCL2 and acute myeloid leukemia: In the present study, we show that phosphorylation patterns of SR proteins are altered during the development of cytarabine resistance in AML, and that the combination of spliceosome inhibitors and other approved drugs, including the BCL2 inhibitor venetoclax, improves the therapeutic response in cells from patients with AML, even in a background of cytarabine resistance.